Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Novel drug targets for MDS

Stephen Nimer • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes APR-246 Luspatercept Venetoclax

Stephen Nimer, MD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses some of the drug targets for novel treatment options. Specifically, he mentions the potential of using APR246, venetoclax or luspatercept in combination with hypomethylating agents (HMA). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Stephen Nimer

1:18
Update on immunotherapy in MDS
Stephen Nimer • 5 Mar 2020
0:53
How to improve transplant outcomes in MDS?
Stephen Nimer • 5 Mar 2020
1:02
Stephen Nimer: MDS highlights
Stephen Nimer • 5 Mar 2020
1:19
The promise of precision medicine in MDS
Stephen Nimer • 5 Mar 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals